Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences Co., Ltd. has scheduled a board meeting for 13 March 2026 to review and approve the group’s final results for the financial year ended 31 December 2025. The board will also consider whether to recommend a final dividend and may address other corporate matters, signaling an upcoming disclosure of the company’s financial performance and potential shareholder returns.
The announcement provides a formal timeline for investors and other stakeholders to expect the company’s year-end financial information. It also underscores the role of the board, led by chairman Xiong Jun and comprising a mix of executive, non-executive and independent directors, in overseeing financial reporting and capital allocation decisions that could affect market perception and shareholder value.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$22.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong, operating through a group structure that includes multiple subsidiaries. The company is overseen by a board comprising executive, non-executive and independent non-executive directors, reflecting a typical governance framework for a listed healthcare enterprise.
Average Trading Volume: 3,093,668
Technical Sentiment Signal: Sell
Current Market Cap: HK$35.03B
Learn more about 1877 stock on TipRanks’ Stock Analysis page.